UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Advancing innovative clinical trials to efficiently deliver medicines to patients

Nature reviews. Drug discovery, 2022-08, Vol.21 (8), p.543-544

2022

Volltextzugriff (PDF)

Bayesian Applications in Pharmaceutical Development

1st, 2020

Volltextzugriff (PDF)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Alzheimer's & dementia : translational research & clinical interventions, 2021, Vol.7 (1), p.e12112-n/a

2021

Volltextzugriff (PDF)

Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development

Therapeutic innovation & regulatory science, 2023-05, Vol.57 (3), p.417-425

2023

Volltextzugriff (PDF)

Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers

Therapeutic innovation & regulatory science, 2023-05, Vol.57 (3), p.426-435

2023

Volltextzugriff (PDF)

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers

Alzheimer's & dementia : translational research & clinical interventions, 2023-10, Vol.9 (4), p.e12421-n/a

2023

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

Clinical therapeutics, 2010-02, Vol.32 (2), p.365-379

2010

Volltextzugriff (PDF)

Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer

Systematic reviews, 2014-09, Vol.3 (1), p.102-102, Article 102

2014

Volltextzugriff (PDF)

Design and Execution of Sustainable Decentralized Clinical Trials

Clinical pharmacology and therapeutics, 2023-10, Vol.114 (4), p.802-809

2023

Volltextzugriff (PDF)

Evaluation of the performance of alternative models in analyzing longitudinal data for Alzheimer clinical trials compared to MMRM

Alzheimer's & dementia, 2022-12, Vol.18 (S10), p.n/a

2022

Volltextzugriff (PDF)

Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia

JAD reports, 2021-04, Vol.5 (1), p.321-336

2021

Volltextzugriff (PDF)

Bayesian methods for the design and analysis of noninferiority trials

Journal of biopharmaceutical statistics, 2016-09, Vol.26 (5), p.823-841

2016

Volltextzugriff (PDF)

IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P935-P935

2019

Volltextzugriff (PDF)

PLASMA NF-L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE-AD STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P251-P251

2019

Volltextzugriff (PDF)

P3‐026: IMPLEMENTATION OF DUAL‐PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE‐AD CLINICAL TRIAL

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_18), p.P935-P935

2019

Volltextzugriff (PDF)

P1‐048: PLASMA NF‐L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE‐AD STUDY

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_4), p.P251-P251

2019

Volltextzugriff (PDF)

Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics

Statistics in biopharmaceutical research, 2022-01, Vol.14 (1), p.5-21

2022

Volltextzugriff (PDF)

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme: Human/Human trials: Anti‐tau

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis

Journal of thoracic disease, 2018-12, Vol.10 (12), p.6677-6694

2018

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants

British journal of clinical pharmacology, 2012-01, Vol.73 (1), p.93-105

2012

Volltextzugriff (PDF)

Estimation of the inter- and intrasubject variability of the diurnal serum cortisol rhythm in healthy male subjects to evaluate the biomarker potential for drug target engagement

International journal of clinical pharmacology and therapeutics, 2015-03, Vol.53 (3), p.199-205

2015

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Advancing innovative clinical trials to efficiently deliver medicines to patients

Bayesian Applications in Pharmaceutical Development

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development

Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial

Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer

Design and Execution of Sustainable Decentralized Clinical Trials

Evaluation of the performance of alternative models in analyzing longitudinal data for Alzheimer clinical trials compared to MMRM

MEDI1814 selectively reduces free Aβ42 in cerebrospinal fluid of non-clinical species and Alzheimer's disease patients

Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia

Bayesian methods for the design and analysis of noninferiority trials

IMPLEMENTATION OF DUAL-PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE-AD CLINICAL TRIAL

PLASMA NF-L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE-AD STUDY

P3‐026: IMPLEMENTATION OF DUAL‐PHASE FLORBETAPIR PET IN THE MULTICENTER PHASE 2 NAVIGATE‐AD CLINICAL TRIAL

P1‐048: PLASMA NF‐L AS A BIOMARKER FOR NEURODEGENERATION IN MILD AD SUBJECTS IN THE PHASE 2 NAVIGATE‐AD STUDY

Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human

Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human: Neuroimaging / evaluating treatments

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme: Human/Human trials: Anti‐tau

First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis

Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants

Estimation of the inter- and intrasubject variability of the diurnal serum cortisol rhythm in healthy male subjects to evaluate the biomarker potential for drug target engagement

Suchergebnisse filtern